Comment on: “Challenging the Odds: Long‐Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co‐Mutations Treated With Upfront Radiotherapy and Targeted Therapy”

To the Editor: We read with great interest the recent publication entitled “Challenging the Odds: Long-Term Survival in Pediatric Diffuse Midline Glioma With H3 K27M and BRAF V600 Co-Mutations Treated With Upfront Radiotherapy and Targeted Therapy” [1]. Catherine Yu et al. [1] described a rare case of diffuse midline glioma (DMG), H3 K27-altered, with a co-occurring BRAF V600E mutation and demonstrated the safe long-term use of dabrafenib–trametinib targeted therapy. The authors discussed that, to date, it remains unclear whether prolonged survival in MAPK-altered DMG reflects intrinsic tumor biology, therapeutic effect, or a combination of both. From the perspective of a middle-income country, given the challenges in accessing tumor biopsy and, particularly, targeted therapies, we would like to contribute to this discussion by presenting a case of a 11-year-old girl diagnosed with diffuse intrinsic pontine glioma (DIPG), with molecular profiling identifying both H3 K27M and BRAF V600E co-mutations. She presented with paralysis of the sixth and seventh cranial nerves. Spinal magnetic resonance imaging (MRI) showed no evidence of metastatic disease (Figure 1). After biopsy, she underwent focal radiotherapy to a total dose of 54 Gy delivered in 30 daily fractions, without any adjuvant therapy. Surveillance MRIs performed every four months have demonstrated stable disease, and she is currently 24 months from diagnosis without any neurological impairment (Figure 2). As discussed by the authors, Auffret et al. [2] described a cohort of H3 K27-altered DMGs with BRAF co-mutations characterized by extended survival. Ongoing efforts aim to improve the understanding of prognostic factors, including potential therapeutic alternatives [3-5]. Pediatric neuro-oncology care in middle-income countries remains constrained by systemic inequities, particularly in the availability of advanced molecular testing and targeted treatments. Closing this gap is a global priority, essential to prevent geography from dictating prognosis and to deliver equitable care for children with aggressive brain tumors. Furthermore, prospective studies are needed to generate more robust clinical and molecular data to identify which patients may benefit most from novel targeted therapies. We appreciate Dr. Catherine Yu and her colleagues for their valuable contribution and hope that this discussion will further benefit this unique group of patients. The authors declare no conflicts of interest.